Spectrum Pharmaceuticals, Inc. (SPPI) gains 2.65% for July 21

Equities Staff  |

Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) shares gained 2.65%, or $0.09 per share, to close Wednesday at $3.49. After opening the day at $3.39, shares of Spectrum, fluctuated between $3.55 and $3.38. 1,314,483 shares traded hands a decrease from their 30 day average of 2,558,873. Wednesday's activity brought Spectrum,’s market cap to $572,730,149.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future.

Visit Spectrum Pharmaceuticals, Inc.’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Spectrum Pharmaceuticals, Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: Spectrum Pharmaceuticals, Inc.’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content